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Abstract: Medical registries are useful to summarize retrospective
or prospective data in a fashion that, on interpretation, could result
in changes in the standard of care or highlight issues that must be
further investigated in the management of certain diseases. Regis-
tries involve collection of data and registries are only as good as the
fidelity of the data that are collected. There are a number of sources
of error in registry formation. This brief review summarizes the
errors that could influence the quality of the data in a registry and
points out methods that could decrease those errors.
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Medical registries can be defined as the collection of apredetermined set of health and demographic data for
patients with specific problems.1 These data are eventually
placed in a central database and are then analyzed either as a
whole or as fractions of the collected data. Registries have a
number of functions including summarizing the results of
management of a particular disease in a specified way, mon-
itoring and improving quality of care, or as a resource for
epidemiologic research.2 Registries can be generated from
prospective or retrospective data, i.e., in real time or from
sifting through already obtained records that document inter-
mediate and final endpoints for the included individuals.
An underlying premise governing registries is that in
order for them to be useful, the data must be authentic and of
good quality. What are good quality data? Good quality data
can be defined as “the totality of features and characteristics
of a data set that bear on its ability to satisfy the needs that
result from the intended use of the data.”2 This will obviously
depend on how “good” the construction of the data set when
it was conceived, hopefully assuring that all the necessary
aspects of the disease situation can be reconstructed when the
data are harvested (i.e., no important points are missing). This
would certainly be defined as data being “complete,” and data
completeness is the extent to which all necessary data that
could have been registered have actually been registered.
Accuracy of the data is another separate but related aspect of
registry fidelity for the accuracy is the extent to which the
registered data are truthful. Hence, the enemy of all registries
is error. Registries must minimize error simply because
mistakes in clinical research that result in erroneous conclu-
sions could deleteriously change the standard of care for
thousands of patients depending on the incidence of the
disease being studied.3
Data errors have been classified in a number of differ-
ent ways. Some authors divide them as interpretation errors,
documentation errors, and coding errors,4 whereas others
divide data errors into systematic (type I) errors and random
(type II) errors.3 Systematic data errors include those that
frankly ask the wrong questions for the given survey (pro-
gramming errors), or those that result from the inability to
have explicit definitions for the data to be collected, or errors
in the actual way in which the data were collected. Random
data errors are caused by placing the wrong information in the
database either because of errors in transferring the data,
inability to read the original source document correctly be-
cause of misinterpretation of the language or handwriting, or
making typing errors. The two most frequently cited errors
that occur include inaccurate data transcription and program-
ming errors in the software used.2 The more the data are
manipulated or transferred, the greater the chance for error.
Studies examining this phenomenon have reported that the
rates of discrepancies between data fields entered in duplicate
in two different databases can be as high as 27%.5 These
errors can originate from errors in the original document
which is copied into the database, interpretation errors in the
data from the original document or simple data entry errors.3
The clinical research form (CRF) remains the workhorse for
data abstraction for both clinical trials and for registries, and
the average error rate in the published literature for CRF-to-
database audits is 14 errors per 10,000 fields.6 However,
before the data are transferred from the CRF to the final
database, there may already be random errors in the process
of transferring data from source documents into the CRF.
To pick up these errors, there must be source document
verification comparing the original data, such as the med-
ical record, with the study of CRF. It is astounding to
consider that in the literature, the average error rate for
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studies having source document verification is 976 errors
per 10,000 fields, when compared with the average error
rate for published CRF-to-database comparison audits 14
errors per 10,000 fields.6
Therefore, to prevent, as well as to correct, errors
before finalizing the data, all registries should have some
form of quality control or monitoring. These quality assur-
ance measures should be put in place preemptively before
data collection begins. This would involve making sure that
the data collection vehicle is representative, easy to use, for
the most part self-explanatory, or has definitions and foot-
notes accompanying specific headers in the database that give
further qualification of that field. Such quality assurance
measures should make sure that the study is designed so that
the endpoints intended can be retrieved and that the individ-
ual workers, whether they are physicians, students, nurses,
data managers, are trained before the start of the study.
Observational studies suggest that ongoing independent as-
sessment of data quality provides higher quality data, lower
variation, better process control, and lower cost than auditing
at the time of “data lockout.” Moreover, independent and
routine data audits are effective in increasing the quality of
the data.7 Cost-effective methods for assuring quality must be
strongly considered when formulating any data registry. How
this is done can vary depending on geography and funds
allocated and can range from on-site sit down meetings with
all data collectors at which time mentoring will be performed
at a central place, or through video-teleconferencing. Al-
though the study is ongoing, there should be intermittent,
on-site monitoring with review of the sites data, interviewing
of the principal investigators and the data managers. By doing
so, ongoing errors will not be propagated because sources of
confusion can be corrected. Periodic data analyses may also
point to discrepancies between sites that may be due to
misinterpretation of the collection vehicle. Such misconcep-
tions can then be recognized and corrected.
Registries of the future must take advantage of turn of
the century informatics technologies that could, in turn, not
only improve quality but also may be cost effective. Planning
of a registry requires the initiators to determine the most
important questions to be answered and whether there are
enough collaborators on the study with data to accomplish
those aims. The number of partners will depend on the
prevalence of the disease as well as the number of institutions
that have a record of treating significant numbers of individ-
uals with the affliction. Consideration as to how the data are
generated onto the source documents at each institution must
be given, and if possible, there must be increased use of
electronic medical records that can seamlessly download
selected data into the CRFs, and the CRFs should be “online”
with easy to use and self-explanatory fields. This technology
is available only for selected state of the art centers, and
manual data entry for registries remains retrospective in the
majority of cases. However, the data resulting from the
retrospective recording from prospectively collected data
would theoretically decrease error rates. Examples of such
prospective data collections include stage 2 to 4 clinical trials
performed by collaborations or collaborative groups.
CONCLUSIONS
Medical registries require meticulous care and feeding.
Only with compulsive attention to detail in the design of the
questions for the CRF, and with institution of quality assur-
ance measures to insure that the data are abstracted and
transferred correctly, will a medical registry be robust and
contribute to medical care. All too often the abstracting of
data for such registries is left to nonmentored individuals, or
to data managers without appropriate guidance. Errors result
are propagated, unfortunately, to the written word. Every
effort for frequent auditing as well as clarity in the CRF
design and harvesting of the data should be made to avoid
misleading observations.
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